Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

ERF Competes with ERG for Chromatin Binding to Control Oncogenesis

DOI: 10.1158/2159-8290.CD-RW2017-118 Published August 2017
  • Article
  • Info & Metrics
Loading
  • Major finding: In prostate cancer, ERF loss-of-function mutations enhance ERG activity to promote tumorigenesis.

  • Concept:TMPRSS2–ERG may promote prostate tumorigenesis in part by outcompeting ERF at ETS consensus motifs.

  • Impact: Loss of ERF activity promotes ERG-dependent androgen signaling to promote prostate oncogenesis.


Embedded Image

The TMPRSS2–ERG gene fusion drives expression of the normally silent ETS transcription factor ERG in response to androgens in approximately half of prostate cancers. Somatic point mutations in a related repressive ETS gene, ERF, have been identified in a small subset of patients with metastatic prostate cancer without the TMPRSS2–ERG fusion. Bose and colleagues investigated the role of these ERF mutations in prostate tumorigenesis. ERF mutations were found in 1%–3% of patients with prostate cancer, including loss-of-function truncating mutations and missense mutations in the ETS domain that destabilized the protein. ERF deletions were also identified, and both the mutations and deletions were largely found in TMPRSS2–ERG-negative tumors. ERG is not expressed in normal prostate epithelium, and induces prostate tumorigenesis in Pten−/− mice; conversely, ERF is expressed in normal prostate, and ERF depletion promoted prostate tumorigenesis in Pten−/− mice. Further, RNA sequencing revealed that ERF depletion induced a downregulation of basal signature genes and upregulation of genes upregulated by androgen in prostate cancer, altogether suggesting that ERF depletion phenocopies ERG overexpression. In normal human prostate and primary prostate tumors, ERF expression was inversely correlated with androgen transcriptional activity signatures, even in TMPRSS2–ERG+ cells. Mechanistically, ERF and ERG bound competitively to the ETS consensus motif; thus, when ERG expression was low, ERF chromatin binding increased and androgen-induced gene expression was suppressed. Similarly, ERG overexpression reduced ERF chromatin occupancy. Moreover, in vivo depletion of ERF accelerated the growth of ERG-dependent tumors, and induction of ERF expression prevented tumor formation and blocked androgen-dependent gene expression. Collectively, these findings support a model in which loss of ERF activity, via loss-of-function mutations or competition with TMPRSS2–ERG, promotes ERG-dependent androgen signaling and prostate cancer, and these findings may be relevant to other ETS-driven malignancies.

Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, et al. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature 2017 Jun 14 [Epub ahead of print].

  • ©2017 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 7 (8)
August 2017
Volume 7, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ERF Competes with ERG for Chromatin Binding to Control Oncogenesis
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
ERF Competes with ERG for Chromatin Binding to Control Oncogenesis
Cancer Discov August 1 2017 (7) (8) OF16; DOI: 10.1158/2159-8290.CD-RW2017-118

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
ERF Competes with ERG for Chromatin Binding to Control Oncogenesis
Cancer Discov August 1 2017 (7) (8) OF16; DOI: 10.1158/2159-8290.CD-RW2017-118
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Cell-Intrinsic Programs Partition Nutrients in Tumor Microenvironment
  • Extrachromosomal DNA Can Promote Oncogene Transcription in Trans
  • Transient Rest Reverses Exhaustion of Chimeric Antigen Receptor T Cells
Show more Research Watch

Prostate Cancer

  • Developmental Programs Are Reactivated in Prostate Cancer Metastasis
  • Remaining Prostate Luminal Cells Regenerate after Androgen Deprivation
  • DDR-Defective Metastatic Prostate Cancers Are Susceptible to Olaparib
Show more Prostate Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement